Top

Drugs

Published in:

01-02-2000 | Leading Article

Drug-Resistant Tuberculosis

What Do We Do Now?

Authors: Dr Amalio Telenti, Michael Iseman

Published in: Drugs | Issue 2/2000

Abstract

Drug-resistant tuberculosis (TB) represents a threat to TB control programmes. Erratic and inappropriate use of currently available medications, HIV-TB coinfection, and concern about transmission of drug-resistant strains in the general population all contribute to a worrying picture. What do we do now? In the last few years, there has been considerable progress in the understanding of mechanisms of action and resistance to antituberculosis agents, and in establishing the value of directly observed therapy in preventing treatment failure. However, a limited effort has been devoted to the development of new active compounds or of rapid diagnostic tests, and their relevance to global tuberculosis control has been questioned.

Pablos-Mendez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994–1997. World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance [published erratum appears in N Engl J Med 1998 Jul 9; 339 (2): 139]. N Engl J Med 1998; 338: 1641–9PubMedCrossRef

World Health Organization. WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world. Geneva: World Health Organization, 1997. Also available from: URL: http://www.who.int

David HL. Basis for lack of drug susceptibility of atypical mycobacteria. Rev Infect Dis 1981; 3: 878–84PubMedCrossRef

Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537–44PubMedCrossRef

Ainsa JA, Perez E, Pelicic V, et al. Aminoglycoside 2′-N-acetyltransferase genes are universally present in mycobacteria: characterization of the aac(2′)-Ic gene from Mycobacterium tuberculosis and the aac(2′)-Id gene from Mycobacterium smegmatis. Mol Microbiol 1997; 24: 431–41PubMedCrossRef

Kwon HH, Tomioka H, Saito H. Distribution and characterization of β-lactamases of mycobacteria and related organisms. Tuber Lung Dis 1995; 76: 141–8PubMedCrossRef

Heym B, Honoré N, Truffot-Pernot C, et al. Implications of multidrug resistance for the future of short course chemotherapy of tuberculosis: a molecular study. Lancet 1994; 344: 293–8PubMedCrossRef

Telenti A. Genetics of drug resistant tuberculosis. Thorax 1998; 53: 793–7PubMedCrossRef

Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79: 3–29PubMedCrossRef

10.

Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. In: Hatfull G, Jr Jacobs WR, editors. Molecular genetics of the mycobacteria. Washington: American Society for Microbiology, 2000. In press

11.

Telenti A, Persing DH. Novel strategies for the detection of drug resistance in Mycobacterium tuberculosis. Res Microbiol 1996; 147: 73–9PubMedCrossRef

12.

Head SR, Parikh K, Rogers YH, et al. Solid-phase sequence scanning for drug resistance detection in tuberculosis. Mol Cell Probes 1999; 13: 81–7PubMedCrossRef

13.

Troesch A, Nguyen H, Miyada CG, et al. Mycobacterium species identification and rifampin resistance testing with high-density DNA probe arrays. J Clin Microbiol 1999; 37: 49–55PubMed

14.

Piatek AS, Tygi S, Pol AC, et al. Molecular beacon sequence analysis: a novel approach to the detection of drug resistance in Mycobacterium tuberculosis. Nature Biotech 1998. 16: 359–363CrossRef

15.

Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647–50PubMedCrossRef

16.

Jacobs Jr WJ, Barletta RG, Udani R, et al. Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages. Science 1993; 260: 819–22PubMedCrossRef

17.

Wilson SM, Al-Suwaidi Z, McNerney R, et al. Evaluation of a new rapid bacteriophage-based method for the drug susceptibility testing of Mycobacterium tuberculosis. Nature Med 1997; 3: 465–8PubMedCrossRef

18.

Riska PF, Su Y, Bardarov S, et al. Rapid film-based determination of antibiotic susceptibilities of Mycobacterium tuberculosis strains by using a luciferase reporter phage and the Bronx Box. J Clin Microbiol 1999; 37: 1144–9PubMed

19.

Sudre P, Cohn DL. Mycobacterium tuberculosis resistance: a call for action. Int J Tuberculosis Lung Dis 1998; 2: 609–11

20.

Lazlo A, Rahman M, Raviglione M, et al. Quality assurance programme for drug susceptibility testing for Mycobacterium tuberculosis in the WHO/IUTLD supranational laboratory network: first round of proficiency testing. Int J Tuberculosis Lung Dis 1997; 1: 231–8

21.

van Embden JDA. Molecular epidemiology of tuberculosis [lecture]. American Society of Microbiology (ASM) Conference on Tuberculosis: past, present and future; State of the Art: 1997 July; Coppermountain (CO)

22.

Ordway DJ, Sonnenberg MG, Donahue SA, et al. Drug-resistant strains of Mycobacterium tuberculosis exhibit a range of virulence for mice. Infect Immun 1995; 63: 741–3PubMed

23.

Meissner G. The bacteriology of the tubercle bacillus. In: Barry VC, editor. Chemotherapy of tuberculosis. London: Butter-worths, 1964

24.

Wilson TM, de Lisle GW, Collins DM. Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol 1995; 15: 1009–15PubMedCrossRef

25.

Heym B, Stavropoulos E, Honore N, et al. Effects of over-expression of the alkyl hydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis. Infect Immun 1997; 65: 1395–1401PubMed

26.

Billington O, McHugh T, Gillespie S. The physiological cost of rifampicin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999; 43: 1866–9PubMed

27.

Bifani PJ, Plikaytis BB, Kapur V, et al. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 1996; 275: 452–7PubMedCrossRef

28.

Agerton T, Valway SE, Blinkhorn RJ, et al. Spread of strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, across the United States. Clin Infect Dis 1999; 29: 85–92PubMedCrossRef

29.

Telzak EE, Fazal BA, Pollard CL, et al. Factors influencing time to sputum conversion among patients with smear positive pulmonary tuberculosis. Clin Infect Dis 1997; 25: 666–70PubMedCrossRef

30.

Mitchison D, Nunn P. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Resp Dis 1986; 133: 423–30PubMed

31.

Hong Kong Chest Service, British Medical Research Council. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. Am Rev Respir Dis 1977; 115: 727–35

32.

Crofton JO, Chaulet P, Maher D. Guidelines for the management of drug resistant tuberculosis. Geneva: World Health Organization, 1997. Also available from: URL: http://www.who.int

33.

Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784–91PubMedCrossRef

34.

Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527–32PubMedCrossRef

35.

Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial infections. Clin Infect Dis 1997; 25: 1213–21PubMedCrossRef

36.

Ji B, Lounis N, Maslo C, et al. In vitro and in vivo activities of moxifloxacin and clinafloxaxin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 2066–9PubMed

37.

Herbert D, Paramasivan CN, Venkatesan P, et al. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 2296–9PubMed

38.

Hackbarth CJ, Unsal I, Chambers HF. Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 1182–5PubMed

39.

Chambers HF, Kocagoz S, Sipit T, et al. Activity of amoxicillin-clavulanate in patients with tuberculosis. Clin Infect Dis 1998; 26: 874–7PubMedCrossRef

40.

Segura C, Salvado M, Collado I, et al. Contribution of beta-lactam susceptibilities of susceptible and multidrug-resistant M tuberculosis clinical isolates. Antimicrob Agents Chemother 1998; 42: 1524–6PubMed

41.

Chambers HF, Moreau D, Yajko D, et al. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob Agents Chemother 1995; 39: 2620–4PubMedCrossRef

42.

Barbachyn MR, Hutchinson DK, Brickner SJ, et al. Identification of a novel oxazolidinone (U-100480) with potent anti-mycobacterial activity. J Med Chem 1996; 39: 680–5PubMedCrossRef

43.

Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel osazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839–45PubMed

44.

Eustice DC, Feldmann GM, Zajac I, et al. Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother 1988; 32: 1218–22PubMedCrossRef

45.

Cynamon M, Klemens SP, Sharpe CA, et al. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999; 43: 1189–91PubMed

46.

Bryskier A. Novelties in the field of anti-infectives in 1997. Clin Infect Dis 1998; 27: 865–83PubMedCrossRef

47.

Slayden RA, Lee RE, Armour JW, et al. Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob Agents Chemother 1996; 40: 2813–19PubMed

48.

Phetsuksiri B, Baulard AR, Cooper AM, et al. Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. Antimicrob Agents Chemother 1999; 43: 1042–51PubMed

49.

Rastogi N, Seng Goh K, David HL. Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis. Antimicrob Agents Chemother 1990; 34: 759–64PubMedCrossRef

50.

Khoo KH, Douglas E, Azadi P, et al. Truncated structural variants of lipoarabinomannan in ethambutol drug-resistant strains of Mycobacterium smegmatis: inhibition of arabinan biosynthesis by ethambutol. J Biol Chem 1996; 271: 28682–90PubMedCrossRef

51.

Bodmer T, Zürcher G, Imboden I, et al. Molecular basis of rifabutin susceptibility in rifampicin resistant M tuberculosis. J Antimicrob Chemother 1995; 35: 345–8PubMedCrossRef

52.

Moghazeh SL, Pan X, Arain T, et al. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 1996; 40: 2655–7PubMed

53.

World Health Organization (WHO). Global tuberculosis control: WHO report. Geneva: WHO, 1999

54.

Mushtaque A, Chowdhury R. Success with the DOTS strategy. Lancet 1999; 353: 1003–4PubMedCrossRef

55.

Iseman MD. MDR-TB and the developing world — a problem no longer to be ignored: the WHO announces DOTS-plus strategy. Int J Tuberculosis Lung Dis 1998; 2: 867

56.

Frieden TR, Sherman DR, Maw K, et al. A multi-institutional outbreak of highly resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276: 1229–35PubMedCrossRef

57.

Fennelly K, Nardell E. The relative efficacy of respirators and room ventilation in preventing occupational tuberculosis. Inf Control Hosp Epidemiol 1998; 19: 754–9CrossRef

58.

Rose DN. Short course prophylaxis against tuberculosis in HIV-infected persons: a decision and cost-effective analysis. Ann Intern Med 1998; 129: 779–86PubMed

59.

Fang Z, Doig C, Rayner A, et al. Molecular evidence for heterogeneity of the multiple-drug-resistant Mycobacterium tuberculosis population in Scotland (1990 to 1997). J Clin Microbiol 1999; 37: 998–1003PubMed

Title: Drug-Resistant Tuberculosis
What Do We Do Now?
Authors: Dr Amalio Telenti
Michael Iseman
Publication date: 01-02-2000
Publisher: Springer International Publishing
Published in: Drugs / Issue 2/2000
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200059020-00002

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Drug-Resistant Tuberculosis

What Do We Do Now?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2000

Dexmedetomidine

Tacrolimus

Lidocaine Patch 5%

Azimilide

Lidocaine Patch 5%

Dexmedetomidine